Author:
Uyl-de Groot Carin A.,Löwenberg Bob
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. International Agency for Research on Cancer & World Health Organization. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. IARC
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
(2017).
2. Luengo-Fernandez, R. et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14, 1165–1174 (2013).
3. Davis, C. et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–2013. BMJ 359, j4530 (2017).
4. Chandra, A., Shafrin, J. & Dhawan, R. Utility of cancer value frameworks for patients, payers, and physicians. JAMA. 315, 2069–2070 (2016).
5. OncLive. Enzalutamide pricing debate goes to Washington. OncLive
http://www.onclive.com/publications/oncology-business-news/2016/may-2016/enzalutamide-pricing-debate-goes-to-washington
(2016).
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献